I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| GABAergic neuron | 3 studies | 31% ± 3% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| GABAergic neuron | 3 studies | 31% ± 3% |
Insufficient scRNA-seq data for expression of ELFN1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 85% | 324.21 | 2242 / 2642 | 90% | 11.75 | 632 / 705 |
| kidney | 99% | 349.24 | 88 / 89 | 69% | 7.90 | 622 / 901 |
| liver | 99% | 1310.87 | 223 / 226 | 67% | 12.55 | 271 / 406 |
| esophagus | 86% | 117.29 | 1239 / 1445 | 78% | 6.78 | 143 / 183 |
| thymus | 95% | 182.26 | 620 / 653 | 60% | 8.02 | 366 / 605 |
| skin | 84% | 144.22 | 1514 / 1809 | 67% | 9.32 | 316 / 472 |
| breast | 97% | 294.54 | 445 / 459 | 52% | 1.89 | 585 / 1118 |
| stomach | 67% | 94.84 | 242 / 359 | 67% | 3.37 | 192 / 286 |
| intestine | 85% | 115.79 | 819 / 966 | 47% | 1.98 | 246 / 527 |
| uterus | 98% | 475.88 | 167 / 170 | 31% | 3.05 | 142 / 459 |
| pancreas | 58% | 52.11 | 190 / 328 | 61% | 3.85 | 108 / 178 |
| bladder | 81% | 109.81 | 17 / 21 | 36% | 1.53 | 179 / 504 |
| lung | 76% | 111.06 | 437 / 578 | 41% | 2.61 | 470 / 1155 |
| adrenal gland | 66% | 77.14 | 170 / 258 | 47% | 7.20 | 107 / 230 |
| prostate | 94% | 213.17 | 231 / 245 | 16% | 0.48 | 81 / 502 |
| eye | 0% | 0 | 0 / 0 | 100% | 91.91 | 80 / 80 |
| heart | 100% | 522.78 | 860 / 861 | 0% | 0 | 0 / 0 |
| adipose | 99% | 418.44 | 1196 / 1204 | 0% | 0 | 0 / 0 |
| spleen | 99% | 211.41 | 238 / 241 | 0% | 0 | 0 / 0 |
| ovary | 37% | 75.55 | 67 / 180 | 49% | 2.37 | 212 / 430 |
| blood vessel | 66% | 89.75 | 877 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 28% | 22.50 | 228 / 803 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 27% | 1.16 | 12 / 45 |
| lymph node | 0% | 0 | 0 / 0 | 10% | 0.24 | 3 / 29 |
| peripheral blood | 4% | 3.17 | 35 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0050808 | Biological process | synapse organization |
| GO_0005615 | Cellular component | extracellular space |
| GO_0060076 | Cellular component | excitatory synapse |
| GO_0031012 | Cellular component | extracellular matrix |
| GO_0016020 | Cellular component | membrane |
| GO_0030425 | Cellular component | dendrite |
| GO_0004864 | Molecular function | protein phosphatase inhibitor activity |
| Gene name | ELFN1 |
| Protein name | Protein ELFN1 (Extracellular leucine-rich repeat and fibronectin type-III domain-containing protein 1) (Protein phosphatase 1 regulatory subunit 28) |
| Synonyms | PPP1R28 |
| Description | FUNCTION: Postsynaptic protein that regulates circuit dynamics in the central nervous system by modulating the temporal dynamics of interneuron recruitment. Specifically present in excitatory synapses onto oriens-lacunosum molecular (OLM) interneurons and acts as a regulator of presynaptic release probability to direct the formation of highly facilitating pyramidal-OLM synapses (By similarity). Inhibits phosphatase activity of protein phosphatase 1 (PP1) complexes. . |
| Accessions | ENST00000561626.4 ENST00000691883.1 ENST00000424383.5 P0C7U0 |
